UPDATE: ICAN Gains Access to Additional Batch Information – Now Including J&J COVID-19 Vaccine Data
ICAN has successfully obtained unique batch and dose information for the Johnson & Johnson (Janssen) COVID-19 vaccine. Similar to the previously acquired Pfizer and Moderna batch and dose data by ICAN, this new information could potentially reveal if certain batches were linked to an elevated number of adverse reactions or fatalities. OpenVAERS has performed an analysis of this newly acquired data.
ICAN recently made headlines by securing extensive batch and dose details for the Pfizer and Moderna mRNA vaccines from the CDC. ICAN now reports that it has also acquired vital batch and dose data for the Johnson & Johnson (J&J) vaccine.
Once more, ICAN has shared this information with OpenVAERS, which has included the J&J data on its COVID-19 Vaccine Lots page. OpenVAERS has analyzed this batch data and, similar to its findings with the Pfizer and Moderna vaccines, observed that the most concerning batches seem to be among those initially distributed.
This data represents the result of a two-and-a-half-year legal struggle. Although the CDC previously released some batch data reluctantly, ICAN’s legal team continued their efforts and ultimately obtained the most comprehensive dataset to date, including never-before-released batch and dose information. This data may now enable the public to ascertain whether the doses they or their loved ones received were part of a potentially “high-risk batch.”
It’s important to note that discovering multiple “high-risk” batches might indicate that the issue lies not with specific batches but with the COVID-19 vaccine products as a whole.
The J&J, Moderna, and Pfizer data are available for download. OpenVAERS’ analysis of this data can be accessed as well. ICAN continues to encourage everyone to examine the raw data and conduct their own analysis.